BRPI0816130A2 - Métodos para a fabricação de uma preparação e para aumentar a resistência a uma infecção viral em um indivíduo. - Google Patents

Métodos para a fabricação de uma preparação e para aumentar a resistência a uma infecção viral em um indivíduo.

Info

Publication number
BRPI0816130A2
BRPI0816130A2 BRPI0816130-5A2A BRPI0816130A BRPI0816130A2 BR PI0816130 A2 BRPI0816130 A2 BR PI0816130A2 BR PI0816130 A BRPI0816130 A BR PI0816130A BR PI0816130 A2 BRPI0816130 A2 BR PI0816130A2
Authority
BR
Brazil
Prior art keywords
individual
preparation
making
methods
viral infection
Prior art date
Application number
BRPI0816130-5A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Otfried Kistner
Christa Tauer
Noel Barrett
Wolfgang Mundt
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of BRPI0816130A2 publication Critical patent/BRPI0816130A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/112Retroviridae (F), e.g. leukemia viruses
    • C07K16/114Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/06Inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0816130-5A2A 2007-08-28 2008-08-28 Métodos para a fabricação de uma preparação e para aumentar a resistência a uma infecção viral em um indivíduo. BRPI0816130A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96672407P 2007-08-28 2007-08-28
PCT/US2008/074559 WO2009029695A1 (en) 2007-08-28 2008-08-28 Method for producing viral vaccines

Publications (1)

Publication Number Publication Date
BRPI0816130A2 true BRPI0816130A2 (pt) 2015-02-24

Family

ID=39947984

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816130-5A2A BRPI0816130A2 (pt) 2007-08-28 2008-08-28 Métodos para a fabricação de uma preparação e para aumentar a resistência a uma infecção viral em um indivíduo.

Country Status (16)

Country Link
US (2) US8497112B2 (enExample)
EP (1) EP2192917B1 (enExample)
JP (1) JP5535910B2 (enExample)
KR (1) KR101760844B1 (enExample)
CN (1) CN101790381B (enExample)
AU (1) AU2008293513B2 (enExample)
BR (1) BRPI0816130A2 (enExample)
CA (1) CA2696090C (enExample)
ES (1) ES2459166T3 (enExample)
HR (1) HRP20140375T1 (enExample)
IL (1) IL203869A (enExample)
PL (1) PL2192917T3 (enExample)
RU (1) RU2496519C2 (enExample)
SG (1) SG10201404101RA (enExample)
SI (1) SI2192917T1 (enExample)
WO (1) WO2009029695A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20090220541A1 (en) * 2005-11-04 2009-09-03 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
CN101784283A (zh) * 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
GB0918830D0 (en) * 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
CN102858961A (zh) * 2010-05-03 2013-01-02 葛兰素史密丝克莱恩生物有限公司 新方法
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
RU2565827C2 (ru) * 2011-07-20 2015-10-20 Эбботт Байолоджикалз Б.В. Способ получения вирусного антигена и вакцин
EP2737060B1 (en) * 2011-07-27 2019-03-06 Flash Therapeutics Method for the production of retroviral particles useful for transducing eukaryotic cells
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
JP6522606B2 (ja) * 2013-10-22 2019-05-29 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 乾燥血斑からの細胞遊離性ウイルス粒子の測定方法
FR3025107B1 (fr) 2014-08-29 2018-10-05 Calixar Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
CN111979120B (zh) * 2019-05-23 2022-09-27 比欧联科供应链管理(北京)有限公司 一种狂犬疫苗核酸消化去除装置及实验方法
RU2754398C1 (ru) * 2020-06-25 2021-09-01 Общество с ограниченной ответственностью «ФОРТ» Способ получения четырехвалентной вакцины для профилактики гриппа

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (enExample) * 1974-01-14 1977-07-15 Sandoz Ag
FR2475572A1 (fr) 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
FR2533548B1 (fr) * 1982-09-28 1985-07-26 Degremont Procede et appareil de traitement anaerobie d'eaux residuaires dans un filtre a remplissage de materiau granulaire
EP0172433A3 (en) * 1984-08-02 1989-04-05 Tektronix, Inc. Display method and apparatus employing cursor panning
GB9110808D0 (en) * 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
RU2082433C1 (ru) * 1992-07-13 1997-06-27 Николай Владимирович Костючек Способ вакцинопрофилактики гриппа
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
CN1223589A (zh) * 1996-05-06 1999-07-21 美国拜尔公司 包含鹦鹉热衣原体的猫疫苗及其制备方法
AT405939B (de) * 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
KR20010032699A (ko) * 1998-10-05 2001-04-25 무따이 마사히꼬 일본 뇌염 바이러스 감염에 대한 불활성 백신을 위한증강된 면역원 및 그 제조방법
CA2355270A1 (en) * 1998-12-17 2000-06-22 Aventis Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
MXPA03000729A (es) 2000-07-28 2004-11-01 Inspire Pharmaceuticals Inc Metodo para reducir la presion intraocular utilizando derivados de indol.
GB0024089D0 (en) * 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
RU2195959C1 (ru) * 2001-11-02 2003-01-10 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Инактивированная вакцина против синдрома гидроперикардита кур
RU2261111C1 (ru) * 2004-04-08 2005-09-27 Сергеев Виталий Александрович Инактивированная вакцина против вирусных пневмогастроэнтеритов крупного рогатого скота и телят и способ профилактики вирусных пневмогастроэнтеритов
US8703467B2 (en) * 2004-05-27 2014-04-22 Baxter International Inc. Inactivation of a pathogen in a sample by a treatment with formalin and UV light
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine

Also Published As

Publication number Publication date
HK1143328A1 (en) 2010-12-31
KR101760844B1 (ko) 2017-07-24
US8497112B2 (en) 2013-07-30
KR20100075865A (ko) 2010-07-05
IL203869A (en) 2016-05-31
CA2696090A1 (en) 2009-03-05
SG10201404101RA (en) 2014-09-26
RU2010111747A (ru) 2011-10-10
EP2192917B1 (en) 2014-01-29
AU2008293513A1 (en) 2009-03-05
PL2192917T3 (pl) 2014-06-30
CN101790381B (zh) 2014-08-27
US20090060950A1 (en) 2009-03-05
AU2008293513B2 (en) 2013-11-21
WO2009029695A1 (en) 2009-03-05
RU2496519C2 (ru) 2013-10-27
EP2192917A1 (en) 2010-06-09
US20130287811A1 (en) 2013-10-31
JP5535910B2 (ja) 2014-07-02
JP2010537641A (ja) 2010-12-09
ES2459166T3 (es) 2014-05-08
CN101790381A (zh) 2010-07-28
HRP20140375T1 (hr) 2014-06-20
CA2696090C (en) 2017-06-13
SI2192917T1 (sl) 2014-05-30

Similar Documents

Publication Publication Date Title
ZA201107675B (en) Multiple virus resistance in plants
DK2106215T3 (da) Brød med forhøjet arabinoxylo-oligosaccharid-indhold
BRPI0807908A2 (pt) Melhoramentos em composições medicinais.
BRPI0807453A2 (pt) Preparação sólida
BRPI0909770A2 (pt) Vacina, e, kit
SI2126093T1 (sl) Izboljšanje priprave proteinov
BRPI0807896A2 (pt) Fórceps bipolares não-aderentes.
DK2352470T3 (da) Indsætningsanordning
PL2452709T3 (pl) Kaniula
BRPI0915524A2 (pt) conjunto de aerofólio
FI20086250A0 (fi) Sieniendoglukanaasit, niiden valmistus ja käyttö
DK2125048T3 (da) Præparat
BRPI0819642A2 (pt) Método para a formação de uma dentadura para um paciente em uma única visita, e, dentadura
EP2219752A4 (en) BOOMERANG
BRPI0814876A2 (pt) Análogos de pirona fosforilados e métodos
IT1391276B1 (it) Casco perfezionato
DK2132234T3 (da) Acceleratoropløsning
PL2222320T3 (pl) Nowy wyciąg z ostropestu plamistego, sposób przygotowania i zastosowanie
NO2022038I1 (no) ropeginterferon alfa-2b
BRPI1009236A2 (pt) Aperfeiçoamentos em, e referentes a, composições biocidas.
BRPI0920833A2 (pt) preparação de benzonorborbenos
BRPI1015351A2 (pt) resistência à infecção bacteriana
BRPI0918169A2 (pt) entretela com células distanciadoras
BRPI0816364A2 (pt) injetável, solução de injeção e kit de preparação da injeção
EP2094296A4 (en) VACCINE WITH MULTIPLE COMPONENTS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2477 DE 26-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.